Predictive transcriptomic signature of response to axitinib in patients with advanced NETs included in the randomized, double-blind, placebo-controlled AXINET trial (GETNE 1107)

#3768

Introduction: Axitinib in combination with Octreotide LAR significantly improved ORR (13.2 vs 3.2%, OR 4.58, p=0.0045) and PFS (16.6 vs 9.9m, HR 0.71, p=0.017) per central blinded radiological assessment, as compared to placebo and SSA, in 256 patients with EP-NETs included in the AXINET trial (Garcia-Carbonero et al, ESMO 2021). The magnitude of the benefit, however, was limited.

Aim(s): To identify molecular signatures and predictive markers associated with axitinib benefit in NETs.

Materials and methods: Gene expression analysis was performed in the 126 EP-NETs included in the AXINET trial that consented for translational studies. The R package singscore was used to develop a predictive signature that was built using the most relevant genes associated with PFS in axitinib-treated patients based on biological process (BP) pathways and multivariate Cox regression analyses.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: Axitinib, Tyrosine kinase inhibitor, predictive biomarker, signature,